Skip to main content

Partner Day with Daiichi Sankyo

When:

September 26, 2018 2:30 pmSeptember 26, 2018 7:00 pm

Where:

The Illumina Theatre at The Alexandria
10996 Torreyana Road
San Diego, CA 92121

Registration Closed

User-added image

September 26th and 27th, senior leaders from Daiichi Sankyo will be in San Diego to meet with local biotech companies, academic institutions, research organizations, venture capital firms, and the local San Diego Life Sciences community. Throughout the day, Daiichi Sankyo will cover their therapeutic areas of focus for innovation partnering along with an interactive panel discussion. A complimentary networking reception will follow the program.

Daiichi Sankyo Group is dedicated to the creation and supply of innovative pharmaceutical products to address diversified, unmet medical needs of patients in both mature and emerging markets. With over 100 years of scientific expertise and a presence in more than 20 countries, Daiichi Sankyo and its 15,000 employees around the world draw upon a rich legacy of innovation and a robust pipeline of promising new medicines to help people.

In addition to a strong portfolio of medicines for hypertension and thrombotic disorders, under the Group’s 2025 Vision to become a “Global Pharma Innovator with Competitive Advantage in Oncology,” Daiichi Sankyo research and development is primarily focused on bringing forth novel therapies in oncology, including immuno-oncology, with additional focus on new horizon areas, such as pain management, neurodegenerative diseases, heart and kidney diseases, and other rare diseases.

Partner Day Agenda
  • 2:30pm – 3:00pm: Networking
  • 3:00pm – 4:30pm: DS Corporate Overview & Q&A
    • Welcome
      • Stuart Mackey, Global Head of Business Development
    • Corporate Overview
      • Masahiko Ohtsuki, Ph.D., Corporate Officer, VP of BD&L
    • Oncology Therapeutic Area Overview
      • Eric Slosberg, Ph.D., Head, Oncology Translational Development, Global Oncology R&D
    • Specialty Medicine Area Overview
      • Kiminori Nagao, MSc, Global Head, Specialty Medicine Development
      • Seiichiro Kamakura, Ph.D., Global Head of Research
    • Partnering with Daiichi Sankyo
      • Stuart Mackey, Global Head of Business Development
    • Open Q&A Panel Discussion
      • Stuart Mackey, Global Head of Business Development
      • Masahiko Ohtsuki, Ph.D., Corporate Officer, VP of BD&L
      • Tom Held, Head of ADC Task Force
      • Arnaud Lesegretain, Head of AML Franchise
      • Marguerite Hutchinson, VP, Plexxikon, Inc., Daiichi Sankyo Group
      • Eric Slosberg, Ph.D., Head, Oncology Translational Development, Global Oncology R&D
      • Kiminori Nagao, MSc, Global Head, Specialty Medicine Development
      • Seiichiro Kamakura, Ph.D., Global Head of Research
  • 4:30pm – 6:30pm: Networking Reception

Areas of Focus:

One-on-One Meeting Opportunity:

Our extensive experience in the development and commercialization of novel therapeutic agents provides the benefits of a fully integrated pharmaceutical company along with a collaborative mindset, entrepreneurial spirit and flexibility. Our philosophy is simple: We expect that our colleagues demonstrate a passion and drive that is consistent with our company's strategy and vision. Do you share these values? Are you interested in learning how to partner with Daiichi Sankyo? Please submit either a non-confidential corporate deck or one-pager to Oscar Rodarte, Capital Development Specialist, at orodarte@biocom.org as soon as possible but no later than August 24th. Please note that meetings will take place on September 26th between 7:30am and 2:30 pm.

Price of Admission

All Attendees

Today’s Price: 0

Important Dates

Amount

Registration before

Registration before

Registration before

Registration cost

0

Refund before 2018-09-25

0

Refund before

Refund Before

  • Agenda
    Partner Day Agenda
    • 2:30pm – 3:00pm: Networking
    • 3:00pm – 4:30pm: DS Corporate Overview & Q&A
      • Welcome
        • Stuart Mackey, Global Head of Business Development
      • Corporate Overview
        • Masahiko Ohtsuki, Ph.D., Corporate Officer, VP of BD&L
      • Oncology Therapeutic Area Overview
        • Eric Slosberg, Ph.D., Head, Oncology Translational Development, Global Oncology R&D
      • Specialty Medicine Area Overview
        • Kiminori Nagao, MSc, Global Head, Specialty Medicine Development 
        • Seiichiro Kamakura, Ph.D., Global Head of Research 
      • Partnering with Daiichi Sankyo
        • Stuart Mackey, Global Head of Business Development
      • Open Q&A Panel Discussion
        • Stuart Mackey, Global Head of Business Development 
        • Masahiko Ohtsuki, Ph.D., Corporate Officer, VP of BD&L
        • Tom Held, Head of ADC Task Force
        • Arnaud Lesegretain, Head of AML Franchise 
        • Marguerite Hutchinson, VP, Plexxikon, Inc., Daiichi Sankyo Group 
        • Eric Slosberg, Ph.D., Head, Oncology Translational Development, Global Oncology R&D
        • Kiminori Nagao, MSc, Global Head, Specialty Medicine Development 
        • Seiichiro Kumakura, Ph.D., Global Head of Research 
    • 4:30pm – 6:30pm: Networking Reception

     
  • One-on-One Meetings
    One-on-One Meeting Opportunity:
    Our extensive experience in the development and commercialization of novel therapeutic agents provides the benefits of a fully integrated pharmaceutical company along with a collaborative mindset, entrepreneurial spirit and flexibility. Our philosophy is simple: We expect that our colleagues demonstrate a passion and drive that is consistent with our company's strategy and vision. Do you share these values? Are you interested in learning how to partner with Daiichi Sankyo? Please submit either a non-confidential corporate deck or one-pager to Oscar Rodarte, Capital Development Specialist, at orodarte@biocom.org as soon as possible but no later than August 17th. 

    Please note that meetings will take place on September 26th between 7:30am and 2:30pm. 

Registration Closed